指南与共识特殊人群用药治疗药物监测与药物基因组学药物相互作用

泊沙康唑在婴幼儿及儿童中的临床药代动力学与剂量建议

Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.
指南 / 共识 · Clin Pharmacokinet · 2019-01-01

该研究基于117名5月龄至18岁免疫缺陷患儿治疗药物监测的338份血浆样本,建立群体药代动力学模型,评估片剂与混悬剂相对生物利用度及腹泻、质子泵抑制剂等协变量影响,并模拟推荐起始剂量。

要点

  • 混悬剂生物利用度随剂量增加而下降,产生片剂一半生物利用度的混悬剂剂量为99 mg/m2。
  • 腹泻与合用质子泵抑制剂均与混悬剂生物利用度降低相关。
  • 片剂表观清除率标准化至70 kg个体为15 L/h。

核心结论

  • 在迄今最大规模儿童群体药代动力学研究中,泊沙康唑协变量效应与成人相似。
  • 腹泻或合用质子泵抑制剂患者混悬剂生物利用度低,可能特别限制泊沙康唑在这些患者中的使用。

研究设计与样本

  • 研究从三级儿科医院数据库提取接受治疗药物监测的儿科患者泊沙康唑血浆浓度,并与电子来源和病例笔记回顾收集的协变量合并。
  • 建立变构缩放群体药代动力学模型,考察片剂与混悬剂相对生物利用度及混悬剂非线性生物利用度,并进行逐步协变量模型构建。
  • 共纳入117名5月龄至18岁儿童的338份泊沙康唑血浆浓度样本。

主要发现

  • 采用一室模型,片剂表观清除率标准化至70 kg个体为15 L/h。
  • 混悬剂生物利用度随剂量增加而下降,产生片剂一半生物利用度的混悬剂剂量估计为99 mg/m2。
  • 腹泻和质子泵抑制剂与混悬剂生物利用度降低相关。

临床怎么用

  • 临床对腹泻或合用质子泵抑制剂的患儿使用泊沙康唑混悬剂时,应关注生物利用度降低可能影响暴露。
  • 可根据体重和剂型参考模型模拟的起始剂量建议,并结合治疗药物监测调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objectives of this study were to investigate the population pharmacokinetics of posaconazole in immunocompromised children, evaluate the influence of patient characteristics on posaconazole exposure and perform simulations to recommend optimal starting doses. METHODS: Posaconazole plasma concentrations from paediatric patients undergoing therapeutic drug monitoring were extracted from a tertiary paediatric hospital database. These were merged with covariates collected from electronic sources and case-note reviews. An allometrically scaled population-pharmacokinetic model was developed to investigate the effect of tablet and suspension relative bioavailability, nonlinear bioavailability of suspension, followed by a step-wise covariate model building exercise to identify other important sources of variability. RESULTS: A total of 338 posaconazole plasma concentrations samples were taken from 117 children aged 5 months to 18 years. A one-compartment model was used, with tablet apparent clearance standardised to a 70-kg individual of 15 L/h. Suspension was found to have decreasing bioavailability with increasing dose; the estimated suspension dose to yield half the tablet bioavailability was 99 mg/m2. Diarrhoea and proton pump inhibitors were also associated with reduced suspension bioavailability. CONCLUSIONS: In the largest population-pharmacokinetic study to date in children, we have found similar covariate effects to those seen in adults, but low bioavailability of suspension in patients with diarrhoea or those taking concurrent proton pump inhibitors, which may in particular limit the use of posaconazole in these patients.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Boonsathorn S, Cheng I, Kloprogge F, et al. Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children. Clin Pharmacokinet. 2019. PMID: 29679234. doi:10.1007/s40262-018-0658-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。